Bulbar amyotrophic lateral sclerosis (bulbar ALS), also known as progressive bulbar palsy, is a variant of ALS that initially and predominantly affects the bulbar muscles—those controlling speech, swallowing, and chewing. This form represents approximately 25-30% of all ALS cases and is associated with a poorer prognosis compared to limb-onset ALS[1]. [1]
While the majority of bulbar ALS cases are sporadic, genetic factors play a significant role: [2]
The genetic architecture of bulbar ALS overlaps substantially with classical ALS, reflecting shared pathophysiology despite different clinical presentations. [3]
The neurodegenerative process in bulbar ALS involves multiple interconnected pathways: [4]
The bulbar region shows particular vulnerability due to: [5]
Dysarthria (slurred speech): Initial symptom in majority of cases[5]
Dysphagia (swallowing difficulty)[5]
Tongue atrophy and fasciculations[5]
Salivary dysfunction[5]
| Stage | Timeline | Clinical Features | [6]
|-------|----------|-------------------| [7]
| Early | 0-12 months | Isolated bulbar symptoms, intact limb function | [8]
| Middle | 12-24 months | Progressive bulbar dysfunction, upper limb involvement | [9]
| Late | 24-36 months | Severe dysphagia, respiratory compromise, quadriparesis |
| End-stage | >36 months | Complete paralysis, respiratory failure |
Cranial nerve examination:
Motor examination:
The diagnosis follows the Awaji or El Escorial criteria[6]:
| Test | Purpose |
|---|---|
| Electromyography (EMG) | Confirm diffuse motor neuron involvement |
| Nerve conduction studies | Exclude peripheral neuropathy |
| MRI brain/cervical spine | Exclude structural lesions |
| CSF analysis | Rule out inflammatory/infectious processes |
| Genetic testing | C9orf72, SOD1, TARDBP, FUS mutations |
| Pulmonary function tests | Assess respiratory involvement |
Disease-modifying therapies[7]:
Symptomatic management:
Speech and language therapy:
Nutritional support:
Respiratory care[7]:
Multidisciplinary care:
| Factor | Impact |
|---|---|
| Older age at onset | Worse prognosis |
| Female sex | Slightly worse prognosis |
| Shorter diagnostic delay | Worse prognosis |
| Pseudobulbar affect early | Poorer outcome |
| Respiratory involvement at diagnosis | Significantly worse |
| C9orf72 expansion | Variable impact |
Active areas of investigation include[8]:
Recent research on Bulbar Amyotrophic Lateral Sclerosis includes:
Chio A, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review. Neuroepidemiology. 2013. 2013. ↩︎
Hardiman O, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017. 2017. ↩︎
Renton AE, et al. A hexanucleotide repeat expansion in C9orf72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011. 2011. ↩︎
Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006. 2006. ↩︎
Kiernan MC, et al. Amyotrophic lateral sclerosis. Lancet. 2011. 2011. ↩︎
Brooks BR, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000. 2000. ↩︎
Miller RG, et al. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies. Neurology. 2009. 2009. ↩︎
Van Damme P, et al. New perspectives for ALS therapy. Nat Rev Neurol. 2017. 2017. ↩︎
Lu CH, et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015. 2015. ↩︎